ARTICLE · 25 SEPTEMBER 2026
Trends In 2026 M&A Dealmaking
Life sciences M&A activity surged in the first half of 2026 with 86 transactions totaling $196 billion, marking a 141% increase over the previous year and the strongest start since 2019. The resurgence is driven by an impending patent cliff threatening $305 billion in revenue, abundant dry powder on pharma balance sheets, and attractive target valuations. With companies increasingly focused on de-risked Phase II and beyond assets, and private equity emerging as optimization partners, the industry is positio
United StatesFinance and Banking
Newsflash. Life sciences M&A is officially back! The first half of 2026 we saw 86 life sciences M&A transactions close, representing a total deal value of $196 billion (and a 141% increase in deal value over the same period last year) and the best start to the year since 2019.1 As we predicted coming out of the J.P. Morgan Healthcare Conference in January, the ingredients were in place for a strong year for dealmaking, and the industry delivered. A significant and enduring trend is a movement over the last several years to focus on de-risked assets. Companies with Phase II assets and beyond now comprise approximately 70% of deals as compared to only 50% of assets in 2021. No surprise, Phase III and approved assets command the greatest premiums.2 Also, interestingly, participation has not been limited to big pharma and big biotech; mid-sized companies have also been more active this year. Most of the M&A are billion dollar or so “bolt-ons” thus far, but the “mega merger” logjam may
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source